Proteolytic cleavage of high mobility group box 1 protein by thrombin - Thrombomodulin complexes

被引:164
作者
Ito, Takashi [1 ]
Kawahara, Ko-ichi [1 ]
Okamoto, Kohji [2 ]
Yamada, Shingo [3 ]
Yasuda, Minetsugu [4 ]
Imaizumi, Hitoshi [5 ]
Nawa, Yuko [1 ,5 ]
Meng, Xiaojie [1 ]
Shrestha, Binita [1 ]
Hashiguchi, Teruto [1 ]
Maruyama, Ikuro [1 ]
机构
[1] Kagoshima Univ, Grad Sch Med & Dent Sci, Lab & Vasc Med, Kagoshima 8908520, Japan
[2] Univ Occupat & Environm Hlth, Sch Med, Dept Surg 1, Kitakyushu, Fukuoka 807, Japan
[3] Shino Test Corp, Sagamihara, Kanagawa, Japan
[4] Hamamatsu Univ Sch Med, Dept Surg 1, Hamamatsu, Shizuoka, Japan
[5] Sapporo Med Univ, Sch Med, Dept Traumatol & Crit Care Med, Sapporo, Hokkaido, Japan
关键词
high mobility group box 1; sepsis; disseminated intravascular coagulation; thrombin; thrombomodulin;
D O I
10.1161/ATVBAHA.107.150631
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective -High mobility group box 1 protein (HMGB1) was identified as a mediator of endotoxin lethality. We previously reported that thrombomodulin (TM), an endothelial thrombin-binding protein, bound to HMGB1, thereby protecting mice from lethal endotoxemia. However, the fate of HMGB1 bound to TM remains to be elucidated. Methods and Results -TM enhanced thrombin-mediated cleavage of HMGB1. N-terminal amino acid sequence analysis of the HMGB1 degradation product demonstrated that thrombin cleaved HMGB1 at the Arg10-Gly11 bond. Concomitant with the cleavage of the N-terminal domain of HMGB1, proinflammatory activity of HMGB1 was significantly decreased (P < 0.01). HMGB1 degradation products were detected in the serum of endotoxemic mice and in the plasma of septic patients with disseminated intravascular coagulation (DIC), indicating that HMGB1 could be degraded under conditions in which proteases were activated in the systemic circulation. Conclusions -TM not only binds to HMGB1 but also aids the proteolytic cleavage of HMGB1 by thrombin. These findings highlight the novel antiinflammatory role of TM, in which thrombin -TM complexes degrade HMGB1 to a less proinflammatory form.
引用
收藏
页码:1825 / 1830
页数:6
相关论文
共 40 条
[1]   The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism [J].
Abeyama, K ;
Stern, DM ;
Ito, Y ;
Kawahara, K ;
Yoshimoto, Y ;
Tanaka, M ;
Uchimura, T ;
Ida, N ;
Yamazaki, Y ;
Yamada, S ;
Yamamoto, Y ;
Yamamoto, H ;
Iino, S ;
Taniguchi, N ;
Maruyama, I .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (05) :1267-1274
[2]   Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation [J].
Bakhtiari, K ;
Meijers, JCM ;
de Jonge, E ;
Levi, M .
CRITICAL CARE MEDICINE, 2004, 32 (12) :2416-2421
[3]   Heparan sulphate proteoglycans fine-tune mammalian physiology [J].
Bishop, Joseph R. ;
Schuksz, Manuela ;
Esko, Jeffrey D. .
NATURE, 2007, 446 (7139) :1030-1037
[4]   The immunopathogenesis of sepsis [J].
Cohen, J .
NATURE, 2002, 420 (6917) :885-891
[5]  
CONWAY EM, 1993, BLOOD, V81, P726
[6]   Do-all receptor takes on coagulation, inflammation [J].
Esmon, C .
NATURE MEDICINE, 2005, 11 (05) :475-477
[7]   The protein C pathway [J].
Esmon, CT .
CHEST, 2003, 124 (03) :26S-32S
[8]   THE REGULATION OF NATURAL ANTICOAGULANT PATHWAYS [J].
ESMON, CT .
SCIENCE, 1987, 235 (4794) :1348-1352
[9]   Dysfunction of endothelial protein C activation in severe meningococcal sepsis. [J].
Faust, SN ;
Levin, M ;
Harrison, OB ;
Goldin, RD ;
Lockhart, MS ;
Kondaveeti, S ;
Laszik, Z ;
Esmon, CT ;
Heyderman, RS .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (06) :408-416
[10]   RECOMBINANT HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST IN THE TREATMENT OF PATIENTS WITH SEPSIS SYNDROME - RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
FISHER, CJ ;
DHAINAUT, JFA ;
OPAL, SM ;
PRIBBLE, JP ;
BALK, RA ;
SLOTMAN, GJ ;
IBERTI, TJ ;
RACKOW, EC ;
SHAPIRO, MJ ;
GREENMAN, RL ;
REINES, HD ;
SHELLY, MP ;
THOMPSON, BW ;
LABRECQUE, JF ;
CATALANO, MA ;
KNAUS, WA ;
SADOFF, JC ;
ASTIZ, M ;
CARPATI, C ;
BONE, RC ;
FREIDMAN, B ;
MURE, AJ ;
BRATHWAITE, C ;
SHAPIRO, E ;
MELHORN, L ;
TAYLOR, R ;
KEEGAN, M ;
OBRIEN, J ;
SCHEIN, R ;
PENA, M ;
WASSERLOUF, M ;
OROPELLO, J ;
BENJAMIN, E ;
DELGUIDICE, R ;
EMMANUEL, G ;
LIE, T ;
ANDERSON, L ;
MARSHALL, J ;
DEMAJO, W ;
ROTSTEIN, O ;
FOSTER, D ;
ABRAHAM, E ;
MIDDLETON, H ;
PERRY, C ;
LEVY, H ;
FRY, DE ;
SIMPSON, SQ ;
CROWELL, RE ;
NEIDHART, M ;
STEVENS, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (23) :1836-1843